Novartis and SciNeuro Pharmaceuticals Forge $1.7 Billion Alzheimer’s Drug Development Deal

On January 12, 2026, Swiss pharmaceutical company Novartis signed a licensing agreement valued at nearly $1.7 billion with China’s SciNeuro Pharmaceuticals to develop antibody treatments for Alzheimer’s disease. This collaboration aims to leverage SciNeuro's proprietary blood-brain barrier shuttle technology, which enhances the delivery of therapeutic agents to the brain, a critical factor in treating Alzheimer's, a condition affecting approximately 55 million people globally.

South China Morning PostReutersNovartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Under the terms of the agreement, SciNeuro will receive an upfront payment of $165 million and has the potential to earn up to $1.5 billion through various development, regulatory, and sales milestones, in addition to royalties on future sales. Novartis will take over the clinical testing and commercialization of the drugs once early-stage development is completed. This partnership is positioned to advance the search for innovative treatments for Alzheimer’s, which has increasingly shifted towards addressing the disease through multiple biological pathways rather than solely targeting amyloid beta proteins.

ReutersSouth China Morning PostNovartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

The collaboration is significant as it combines SciNeuro's expertise in neurodegenerative diseases with Novartis' global leadership in drug development and commercialization. Li Min, founder and CEO of SciNeuro, emphasized that this partnership represents a strategic priority for the company, aiming to synergize their research capabilities with Novartis' extensive resources.

South China Morning Post

Despite the optimism surrounding this partnership, the search for effective Alzheimer’s treatments has faced skepticism. Current approved treatments, such as Biogen's Leqembi and Eli Lilly's Kisunla, have seen limited uptake due to concerns regarding their cost, efficacy, and side effects. Critics argue that the focus on amyloid beta may not address the complexity of Alzheimer’s disease, which involves various biological mechanisms.

Reuters

Novartis stated that the deal would allow them to access innovative technologies that could differentiate their antibody treatments from existing options. The company aims to work closely with SciNeuro during the early stages of development before assuming responsibility for further clinical trials and global commercialization.

Reuters

The deal is expected to close in the first half of 2026, marking a significant step in the ongoing efforts to develop new therapies for Alzheimer’s disease. As the partnership progresses, both companies will focus on advancing their research and development initiatives to bring potentially transformative treatments to market.

Reuters

• “The anti-amyloid programme represents one of SciNeuro’s key strategic research and development priorities to target the neurodegenerative disease,” — Li Min, Founder and CEO of SciNeuro

South China Morning Post

• “This collaboration delivers an optimal synergy, combining our expertise in disease biology and early development with Novartis’ global leadership in clinical development and commercialisation.” — Li Min, Founder and CEO of SciNeuro

South China Morning Post

This partnership between Novartis and SciNeuro highlights a significant investment in the fight against Alzheimer’s disease, reflecting both companies' commitment to addressing a major global health challenge.

South China Morning Post